Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Keynote-D18 might have failed on a technicality, but now cash is running out.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
